Germline BRCA1 and BRCA2 mutations in specific different domains affect ovarian cancer prognosis: A multicenter retrospective study

Correlation between germline *BRCA1/2* mutation domain and ovarian cancer outcomes

A multicenter retrospective study analyzes the prognostic impact of germline BRCA1 and BRCA2 variants by mutated molecular domain in ovarian cancer. Results suggest that variant localization within specific functional domains of BRCA1/2 modulates prognosis and potentially response to targeted therapies (PARP inhibitors). These data refine genotype-phenotype correlations in hereditary ovarian cancer predisposition and could inform surveillance and treatment strategies for carriers.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

These domain-specific data for BRCA1/2 are potentially important for refining genetic counseling beyond simple pathogenic variant identification. The question of predicting PARP inhibitor response by mutated domain is open and promising, even if the study remains retrospective and multicentric without prospective control.